Adagio Medical Holdings, Inc. (ADGM)

NCM – Real vaqt narxi. Valyuta: USD

0.69

-0.03 (-4.03%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

0.69

-0.00 (-0.01%)

Bozordan keyin: Aug 12, 2026, 4:17 PM EDT

11.08.2026

Adagio Medical Reports Second Quarter 2026 Results

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company's next-generation vCLAS™ Ultra Ultra-Low temperature ablation cat.

03.08.2026

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (“ULTA”) system under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”).The patient, who presented with non-ischemic cardiomyopath.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

Adagio Medical Reports Second Quarter 2026 Results

03.08.2026

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (“ULTA”) system under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”).The patient, who presented with non-ischemic cardiomyopath.

Adagio Medical Holdings, Inc. (ADGM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Adagio Medical Holdings, Inc. (ADGM)

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Videolar

No Data

Press-relizlar

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Videolar

No Data

Press-relizlar

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Search stocks

Adagio Medical Holdings, Inc. (ADGM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Adagio Medical Holdings, Inc. (ADGM)

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Videolar

No Data

Press-relizlar

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Videolar

No Data

Press-relizlar

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System